Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

CENTURY CLINICAL LAB, INC.

NPI: 1245469527 · SUNRISE, FL 33326 · Clinical Medical Laboratory · NPI assigned 07/08/2009

$15K
Total Medicaid Paid
6,814
Total Claims
5,030
Beneficiaries
28
Codes Billed
2018-01
First Month
2019-04
Last Month

Provider Details

Authorized OfficialVALDES, RUBEN (CEO)
NPI Enumeration Date07/08/2009

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 4,229 $8K
2019 2,585 $8K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1,524 1,039 $13K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 178 123 $693.11
80053 Comprehensive metabolic panel 696 528 $456.62
85025 Blood count; complete (CBC), automated, and automated differential WBC count 860 622 $238.67
84443 Thyroid stimulating hormone (TSH) 449 329 $226.98
80061 Lipid panel 577 422 $190.22
83036 Hemoglobin; glycosylated (A1C) 216 174 $108.40
82607 58 47 $47.39
81001 210 164 $32.67
84480 32 19 $18.92
87086 Culture, bacterial; quantitative colony count, urine 89 73 $11.85
82746 78 41 $10.94
84550 28 17 $5.48
84436 86 49 $5.10
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 447 428 $0.00
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 15 14 $0.00
P9604 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge 159 128 $0.00
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 23 21 $0.00
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 22 21 $0.00
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 39 37 $0.00
84439 15 12 $0.00
80171 55 55 $0.00
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 29 26 $0.00
36415 Collection of venous blood by venipuncture 741 483 $0.00
84153 43 41 $0.00
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 50 49 $0.00
84479 71 47 $0.00
87503 24 21 $0.00